lysergic acid diethylamide has been researched along with Anxiety Neuroses in 34 studies
Lysergic Acid Diethylamide: Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood.
lysergic acid diethylamide : An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to investigate the efficacy and safety of lysergic acid diethylamide (LSD)-assisted therapy in patients who experienced anxiety with or without association with a life-threatening illness." | 9.69 | Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. ( Dolder, PC; Gasser, P; Holze, F; Liechti, ME; Müller, F, 2023) |
| "A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases." | 9.19 | Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. ( Brenneisen, R; Doblin, R; Gasser, P; Holstein, D; Michel, Y; Passie, T; Yazar-Klosinski, B, 2014) |
| "This study aimed to investigate the efficacy and safety of lysergic acid diethylamide (LSD)-assisted therapy in patients who experienced anxiety with or without association with a life-threatening illness." | 5.69 | Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. ( Dolder, PC; Gasser, P; Holze, F; Liechti, ME; Müller, F, 2023) |
| "A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases." | 5.19 | Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. ( Brenneisen, R; Doblin, R; Gasser, P; Holstein, D; Michel, Y; Passie, T; Yazar-Klosinski, B, 2014) |
| "Lysergic acid diethylamide (LSD) is a potent classic serotonergic psychedelic, which facilitates a variety of altered states of consciousness." | 3.01 | Dose-response relationships of LSD-induced subjective experiences in humans. ( Hirschfeld, T; Majić, T; Prugger, J; Schmidt, TT, 2023) |
| " Psychedelics are generally considered to be physiologically safe with low toxicity and low addictive potential." | 3.01 | Cardiovascular safety of psychedelic medicine: current status and future directions. ( Wsół, A, 2023) |
| "To determine how differences in the type of psychedelic agent used and the number of dosing sessions administered affect subjects' depression and anxiety outcomes and adverse drug reactions (ADR)." | 2.82 | Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis. ( Leger, RF; Unterwald, EM, 2022) |
| " Although several pharmacological treatments are available, they are not effective for a significant proportion of patients and are associated with several adverse reactions." | 2.58 | Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. ( Alcázar-Córcoles, MÁ; Bouso, JC; Dos Santos, RG; Hallak, JEC, 2018) |
| " The third report indicates that intranasal ingestion of 550 times the normal recreational dosage of LSD was not fatal and had positive effects on pain levels and subsequent morphine withdrawal." | 1.56 | LSD Overdoses: Three Case Reports. ( Haden, M; Woods, B, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (47.06) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (23.53) | 24.3611 |
| 2020's | 10 (29.41) | 2.80 |
| Authors | Studies |
|---|---|
| Leger, RF | 1 |
| Unterwald, EM | 1 |
| Hall, W | 1 |
| Kopra, EI | 1 |
| Ferris, JA | 1 |
| Rucker, JJ | 1 |
| McClure, B | 1 |
| Young, AH | 1 |
| Copeland, CS | 1 |
| Winstock, AR | 1 |
| Holze, F | 1 |
| Gasser, P | 3 |
| Müller, F | 1 |
| Dolder, PC | 1 |
| Liechti, ME | 1 |
| Hirschfeld, T | 1 |
| Prugger, J | 1 |
| Majić, T | 1 |
| Schmidt, TT | 1 |
| Hovmand, OR | 1 |
| Poulsen, ED | 1 |
| Arnfred, S | 1 |
| Storebø, OJ | 1 |
| Inserra, A | 1 |
| Piot, A | 1 |
| De Gregorio, D | 1 |
| Gobbi, G | 1 |
| Wsół, A | 1 |
| Haden, M | 1 |
| Woods, B | 1 |
| Snelders, S | 1 |
| Pieters, T | 1 |
| Nichols, DE | 1 |
| Aixalà, M | 1 |
| Dos Santos, RG | 2 |
| Hallak, JEC | 2 |
| Bouso, JC | 2 |
| Alcázar-Córcoles, MÁ | 1 |
| Kvam, TM | 1 |
| Stewart, LH | 1 |
| Andreassen, OA | 1 |
| Muttoni, S | 1 |
| Ardissino, M | 1 |
| John, C | 1 |
| Holstein, D | 1 |
| Michel, Y | 1 |
| Doblin, R | 1 |
| Yazar-Klosinski, B | 1 |
| Passie, T | 2 |
| Brenneisen, R | 1 |
| Kirchner, K | 1 |
| Sessa, B | 1 |
| KAFKALIDIS, A | 1 |
| LING, TM | 1 |
| BUCKMAN, J | 1 |
| HOFFER, A | 1 |
| OSMOND, H | 1 |
| ALNAES, R | 1 |
| SKAUG, OE | 1 |
| SPENCER, AM | 1 |
| Vanggaard, T | 1 |
| LEDINSKA, N | 1 |
| MASIN, Z | 1 |
| Strassman, RJ | 1 |
| Abramson, HA | 1 |
| Linken, A | 1 |
| Cardon, PV | 1 |
| Weiss, JL | 1 |
| Mueller, PS | 1 |
| Krsiak, M | 1 |
| Vinar, O | 1 |
| Waltzer, H | 1 |
| Denson, R | 1 |
| Kielholz, P | 1 |
| Ladewig, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Trial of Visual Healing®, a Nature-themed Virtual Immersive Experience, to Optimize Set and Setting in Psilocybin-assisted Therapy for Alcohol Use Disorder[NCT04410913] | Phase 2 | 20 participants (Actual) | Interventional | 2021-02-18 | Active, not recruiting | ||
| LSD-assisted Psychotherapy in Persons Suffering From Anxiety Associated With Advanced-stage Life Threatening Diseases. A Phase-II, Double-blind, Placebo-controlled Dose-response Pilot Study[NCT00920387] | Phase 2 | 12 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| EMPOWER Study: Exploring Medically Perceived Benefits, Use and Interest in Psychedelics and Cannabinoids: Observational Study With First Responders and Military Personnel Examining Previous Use Experience and Interest in Participating in Future Research S[NCT04965740] | 102 participants (Actual) | Observational | 2021-06-04 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The STAI-state subscale is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety. Participants respond to each item by selecting a response from a 4-point Likert scale ranging from 4 (Not at all) to 1 (Very much so). STAI-state scores are summed for a total score that range from 20 to 80, with higher scores indicating greater state anxiety. The STAI-trait subscale also consists of 20-items and is scored the same way, with total scores ranging from 20 to 80, with higher scores indicating greater trait anxiety." (NCT00920387)
Timeframe: Baseline (Visit 4)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| STAI-state | STAI-trait | |
| Active Placebo LSD (20 mcg) | 47.7 | 43.3 |
| Full Dose LSD (200 mcg) | 53.1 | 53.2 |
"The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The STAI-state subscale is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety. Participants respond to each item by selecting a response from a 4-point Likert scale ranging from 4 (Not at all) to 1 (Very much so). STAI-state scores are summed for a total score that range from 20 to 80, with higher scores indicating greater state anxiety. The STAI-trait subscale also consists of 20-items and is scored the same way, with total scores ranging from 20 to 80, with higher scores indicating greater trait anxiety." (NCT00920387)
Timeframe: 2 months after second experimental session
| Intervention | score on a scale (Mean) | |
|---|---|---|
| STAI-state | STAI-trait | |
| Active Placebo LSD (20 mcg) | 51.7 | 49.0 |
| Full Dose LSD (200 mcg) | 41.5 | 45.2 |
12 reviews available for lysergic acid diethylamide and Anxiety Neuroses
| Article | Year |
|---|---|
Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
Topics: Affect; Anxiety Disorders; Banisteriopsis; Depressive Disorder; Hallucinogens; Humans; Lysergic Acid | 2022 |
Why was early therapeutic research on psychedelic drugs abandoned?
Topics: Anxiety Disorders; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psychiatry; Therapeutic Human | 2022 |
Dose-response relationships of LSD-induced subjective experiences in humans.
Topics: Anxiety; Anxiety Disorders; Consciousness; Hallucinogens; Humans; Lysergic Acid Diethylamide | 2023 |
Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review.
Topics: Anxiety Disorders; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psilocybin; Randomized Control | 2023 |
Lysergic Acid Diethylamide (LSD) for the Treatment of Anxiety Disorders: Preclinical and Clinical Evidence.
Topics: Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Humans; Lysergic Acid Diethylamide; Psychotherapy | 2023 |
Cardiovascular safety of psychedelic medicine: current status and future directions.
Topics: Anxiety Disorders; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mescaline; Psilocybin | 2023 |
Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD).
Topics: Anxiety Disorders; Depressive Disorder; Drug and Narcotic Control; Europe; Hallucinogens; History, 2 | 2018 |
Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Topics: Anxiety Disorders; Banisteriopsis; Depressive Disorder; Hallucinogens; Humans; Lysergic Acid Diethyl | 2018 |
Psychedelic drugs in the treatment of anxiety, depression and addiction.
Topics: Anxiety; Anxiety Disorders; Depression; Depressive Disorder; Hallucinogens; Humans; Lysergic Acid Di | 2018 |
Classical psychedelics for the treatment of depression and anxiety: A systematic review.
Topics: Adult; Anxiety Disorders; Depressive Disorder; Female; Hallucinogens; Humans; Lysergic Acid Diethyla | 2019 |
Adverse reactions to psychedelic drugs. A review of the literature.
Topics: Adolescent; Adult; Anxiety Disorders; Chronic Disease; Hallucinogens; Humans; Lysergic Acid Diethyla | 1984 |
[Clinical psychopharmacology in 1966].
Topics: Anxiety Disorders; Fluphenazine; Humans; Isocarboxazid; Lysergic Acid Diethylamide; Mental Disorders | 1968 |
4 trials available for lysergic acid diethylamide and Anxiety Neuroses
| Article | Year |
|---|---|
Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Topics: Anxiety; Anxiety Disorders; Cross-Over Studies; Double-Blind Method; Humans; Lysergic Acid Diethylam | 2023 |
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.
Topics: Adult; Anxiety; Anxiety Disorders; Combined Modality Therapy; Cross-Over Studies; Female; Follow-Up | 2014 |
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.
Topics: Adult; Anxiety; Anxiety Disorders; Combined Modality Therapy; Cross-Over Studies; Female; Follow-Up | 2014 |
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.
Topics: Adult; Anxiety; Anxiety Disorders; Combined Modality Therapy; Cross-Over Studies; Female; Follow-Up | 2014 |
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.
Topics: Adult; Anxiety; Anxiety Disorders; Combined Modality Therapy; Cross-Over Studies; Female; Follow-Up | 2014 |
LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects.
Topics: Adult; Anxiety Disorders; Double-Blind Method; Emotions; Female; Follow-Up Studies; Humans; Lysergic | 2015 |
Lysergide in the treatment of neurosis. (A report of two cases).
Topics: Adult; Amobarbital; Antisocial Personality Disorder; Anxiety Disorders; Clinical Trials as Topic; De | 1966 |
18 other studies available for lysergic acid diethylamide and Anxiety Neuroses
| Article | Year |
|---|---|
Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD).
Topics: Anxiety Disorders; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Health; Substance-Relat | 2022 |
LSD Overdoses: Three Case Reports.
Topics: Adolescent; Anxiety Disorders; Drug Overdose; Female; Hallucinogens; Humans; Lysergic Acid Diethylam | 2020 |
[The rise, fall, and possible rise of LSD].
Topics: Anxiety; Anxiety Disorders; Hallucinogens; Humans; Lysergic Acid Diethylamide; Substance-Related Dis | 2020 |
Psychedelics and Personality.
Topics: Anxiety Disorders; Banisteriopsis; Clinical Trials as Topic; Hallucinogens; Humans; Lysergic Acid Di | 2018 |
Turn on and tune in to evidence-based psychedelic research.
Topics: Anxiety Disorders; Biomedical Research; Chemotherapy, Adjuvant; Hallucinogens; Humans; Lysergic Acid | 2015 |
[THERAPEUTIC USE OF D-LYSERGIC ACID DIETHYLAMIDE (DELYSIDE OR LSD-25) IN PSYCHONEUROSES].
Topics: Alcoholism; Anxiety; Anxiety Disorders; Humans; Lysergic Acid Diethylamide; Neurotic Disorders; Obse | 1963 |
THE TREATMENT OF ANXIETY WITH LYSERGIC ACID AND METHYL PHENIDATE.
Topics: Anxiety; Anxiety Disorders; Humans; Lysergic Acid; Lysergic Acid Diethylamide; Methylphenidate; Neur | 1963 |
A QUESTION OF INSIGHT.
Topics: Anxiety; Anxiety Disorders; Bipolar Disorder; Depression; Humans; Hysteria; Lysergic Acid Diethylami | 1963 |
[CLINICAL AND PSYCHOPATHOLOGICAL PHENOMENA IN PSYCHOTHERAPY USING LSD CORRELATED WITH BIOCHEMICAL FINDINGS].
Topics: Anxiety; Anxiety Disorders; Blood Chemical Analysis; Humans; Hydrocortisone; Lysergic Acid Diethylam | 1963 |
MODIFICATIONS IN THE TECHNIQUE OF LSD THERAPY.
Topics: Anxiety; Anxiety Disorders; Brain Chemistry; Drug Therapy; Drug Tolerance; Hospital Design and Const | 1964 |
INDICATIONS AND COUNTER-INDICATIONS FOR LSD TREATMENT. OBSERVATIONS AT POWICK HOSPITAL, ENGLAND.
Topics: Anxiety; Anxiety Disorders; Drug Therapy; England; Erectile Dysfunction; Homosexuality; Humans; Lyse | 1964 |
[Anxiety and flight reactions in experimental cerebellar lesions].
Topics: Anxiety; Anxiety Disorders; Cerebellum; Electroencephalography; Escape Reaction; Fear; Lysergic Acid | 1961 |
Reassociation of dreams. III. LSD analysis of a threatening male-female dog dream and its relation to fear of lesbianism.
Topics: Anxiety Disorders; Asthma; Dreams; Eczema; Fear; Female; Guilt; Homosexuality; Humans; Interview, Ps | 1977 |
Propranolol for L.S.D.-induced anxiety states.
Topics: Anxiety Disorders; Depression; Humans; Lysergic Acid Diethylamide; Male; Propranolol; Psychoses, Sub | 1971 |
Effects of small intravenous doses of epinephrine on serum insulin, glucose tolerance and serum free fatty acids.
Topics: Adolescent; Adult; Anxiety Disorders; Biological Assay; Blood Glucose; Caffeine; Epinephrine; Fatty | 1974 |
Proceedings: Isolation-induced timidity in mice as a measure of anxiolytic activity of drugs.
Topics: Animals; Anxiety Disorders; Barbiturates; Chlordiazepoxide; Chlorpromazine; Dextroamphetamine; Diaze | 1974 |
Depersonalization and the use of LSD: a psychodynamic study.
Topics: Adolescent; Aggression; Anxiety Disorders; Attitude; Body Image; Cognition Disorders; Conflict, Psyc | 1972 |
[Drug addiction among juveniles with special consideration of hashish smoking].
Topics: Adolescent; Adult; Anxiety Disorders; Cannabis; Europe; Health Education; Humans; Interpersonal Rela | 1970 |